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Fibromyalgia (FMS) is a valid clinical condition that aﬀects 2%–4% of the population with a pivot symptom of widespread
body pain. The cause and cure of FMS are as yet unknown. The concept of FMS has evolved over the past two decades to
incorporate symptoms beyond pain as contributing to the global spectrum of suﬀering. FMS is now recognized to be grounded
in the neurological domain with evidence of dysregulation of pain processing. Appreciation of the neurophysiologic mechanisms
operativeinFMShascontributedtorationaltreatmentrecommendations,althougha“goldstandardtreatment”doesnotcurrently
exist. Ideal treatments for FMS patients should be individualized with emphasis on active patient participation, good health
practices, and multimodal intervention, incorporating nonpharmacologic and pharmacologic treatments. Predictors of outcome,
which is favourable in over 50% of patients, are unknown, but those with better outcome do more physical activity and use fewer
medications.
1.Introduction
1.1. The Coming of Age after 20 Years. Fibromyalgia (FMS)
is a condition characterized by the pivot symptom of pain
throughout the body, and with abnormality centered in
the nervous system [1]. Over the past 20 years, knowledge
regarding both the clinical as well as the neurophysiological
basisforthisconditionhasaccumulated.FMSaﬀects2%–4%
of populations worldwide and is a cause of considerable suf-
fering and functional impairment [2]. The clinical concept
of FMS was initially described by Yunus and colleagues and
crystallized by the publication of the 1990 American College
of Rheumatology (ACR) criteria for the classiﬁcation of FMS
[3, 4].
An evolution of the clinical understanding of FMS over
thelasttwodecadeshasemphasisedtheimportanceofsymp-
toms beyond pain which form an integral part of this con-
dition and contribute to global suﬀering. In this context, it
became necessary for the criteria for a diagnosis of FMS
to be reevaluated. The coming of age of FMS was heralded
by the publication of updated criteria for the diagnosis of
FMS, taking into consideration additional symptoms that
are present to a variable degree in individual patients [5]. In
addition, the new concept of FMS recognizes that symptoms
are not an all-or-none phenonemon, but can be expressed
with varying severity with periods of waxing and waning [6].
Neurophysiological studies have contributed to the ac-
ceptance of FMS as a valid condition. Demonstration of ob-
jective changes in the research setting has given clinicians the
conﬁdence to acknowledge a condition that presents with
only subjective complaint and no objective clinical ﬁndings
[1]. Dysregulation of pain processing has been demonstrated
a tv a r i o u sl e v e l si nt h en e r v o u ss y s t e m ,b u tw es t i l ll a c ka n
objective test in the clinical setting to conﬁrm a diagnosis
or gauge response to treatments [1, 7] .H o w e v e r ,t h i si sn o
diﬀerentthanotherwell-recognizedconditions,forexample,2 Pain Research and Treatment
irritable bowel syndrome (IBS), migraine, and depression. It
is undeniable that depression is a serious condition and yet it
lacks an objective test.
Even with objective scientiﬁc support of abnormality,
somescepticismstillexistsregardingthevalidityofsubjective
complaints requiring complete reliance on the practice of
the art of medicine [8]. The controversy regarding the ex-
istence of this syndrome should now be put to rest. Eﬀorts
should be directed towards better understanding of the neu-
rophysiological abnormalities, improved clinical recognition
of patients, and translation of mechanistic studies into op-
timizing treatments. In this paper, we will present current
concepts of FMS, which can be applied to the rational man-
agement of these patients. This paper will address current
concepts and challenges pertaining to the clinical under-
standing of FMS.
2. Methods
This paper is based on a review of the literature achieved
by a comprehensive literature search using MEDLINE,
CINAHL,Cochrane,PUBMED,EMBASE,CochraneLibrary,
and PsycINFO. MEDLINE is widely used as a premier source
for biographic coverage of the literature and the CINAHL for
nursing literature. In addition to the formal search, a manual
search from the references cited by original studies and re-
views was also used where indicated.
2.1.TheClinicalChallengeRemains. Cliniciansaretradition-
ally skeptical of any condition wherein there is disconnection
between complaint and physical examination ﬁndings. This
was ﬁrst evident with the construct of phantom limb syn-
drome, now accepted as a real phenomenon and cause of
pain in the absence of anatomical tissue in the periphery
[9]. Beginning in the 1980’s, there were emerging reports
that body pain, in the absence of tissue damage, could be
present [3, 10, 11]. These patients were mostly referred
to rheumatologists in order to rule out some connective
tissue disease. The notion that FMS is indeed a true entity
follows publication of neurophysiological studies attesting to
objective ﬁndings in a clinical condition that was often per-
ceived to be nebulous.
Beginning with their landmark study in 1981, Yunus and
coworkers have championed the recognition of this con-
dition over the past three decades [3]. In this paper, the
authors emphasized that FMS is more than pain, adding
many other symptoms or associated conditions, for exam-
ple, fatigue, stiﬀness (which is a prominent symptom in
some patients), poor sleep, morning fatigue, tension-type
headache, migraine, IBS, subjective swelling (which often
leads to a misdiagnosis of rheumatoid arthritis), subjective
numbness, anxiety, stress and depression, as well as modu-
lating factors of pain and stiﬀness [3].
There have been physicians who have disputed the va-
lidity of a condition presenting with subjective complaints
and associated with considerable functional impairment,
withoutobjectiveclinicalﬁndings.Somehaveevensuggested
that FMS was mostly a manifestation of depression [12, 13].
However, depression and FMS are biologically two diﬀerent
diseases, including an absence of central sensitization in de-
pression by almost all stimuli [14, 15].
The clinical challenge of this condition remains as there
is still no objective clinical ﬁnding or test to conﬁrm the di-
agnosis, or gauge severity of symptoms. Physicians are re-
quired to assess this syndrome on the basis of subjective
report only. This has fostered a sense of clinical uncertainty
leading physicians to often consider a diagnosis of FMS
only when other possible diagnoses have been excluded [16].
This insecurity by health care professionals may be a factor
leading to frequent use of unnecessary investigations and can
contribute to excessive medicalization of patients. It has been
clearly documented that a deﬁnite diagnosis of FMS leads to
reduced health care use and also better global patient health
[17, 18].
2.2. Fibromyalgia Is More Than Just Pain. Initially, FMS was
considered to be a condition of pain, and this concept was
reinforced by the 1990 ACR criteria which only included
features of pain and localized body tenderness [4]. The un-
derstanding of FMS today acknowledges that patients with
F M Sw i l lh a v eas y m p t o mc o m p l e xc h a r a c t e r i z e db ym o r e
than just pain with other complaints present with variable
intensity [19]. Besides those mentioned above, that is, fa-
tigue, sleep disturbance, cognitive changes, and mood disor-
der,othersymptomsorassociatedconditionsincluderestless
legs syndrome, periodic limb movements in sleep, tem-
poromandibular disorder (TMD), multiple chemical sensi-
tivity, and interstitial cystitis [20, 21]. Each of these symp-
toms plays a variable role in the presentation of an individual
patientandallcontributetoagreaterorlesserdegreetowards
the overall eﬀect of impaired quality of life and reduced
functional activity.
The typical patient is female in her 40’s or 50’s with a
few years of ill-deﬁned musculoskeletal pain [22]. Onset of
symptoms is usually gradual, but occasionally there may
be a sudden onset following an identiﬁable event, such as
a medical illness, a mentally stressful incident or physical
trauma. Only 5–7% of the FMS patients are males. The clin-
ical characteristics of FMS among men are similar to those
in women, except that men have fewer symptoms, fewer pain
sites, less frequent fatigue and IBS, and fewer tender points
[23].
Pain is described as being diﬀuse, deep, and continuous
often with periods of exacerbation. Pain symptoms may be
modulated by various factors including psychological stress,
excessive physical activity, fatigue, or changes in the weather
[24]. Some patients also report a superﬁcial burning quality
to pain with increased sensitivity to painful stimuli-termed
hyperalgesia, and may also have features of allodynia or pain
following an innocuous stimulation such as touch [25]. Pain
quality or unpleasantness is an equally important compo-
nent of the pain experience, but is not commonly measured
either in clinical practice or even in the study setting of pa-
tients with FMS.
Multiple symptoms contribute to the burden of suf-
fering and are increasingly recognized as important fromPain Research and Treatment 3
the patient perspective and require attention for achieving
optimal patient care [5, 19, 26]. Nonrestorative sleep is
associated with widespread pain [27]. Many components
of sleep have been measured as abnormal in FMS patients
including sleep latency, sleep disturbance, and impaired
daytime functioning [28]. Poor quality and duration of sleep
has been shown to have a negative impact upon fatigue
and aﬀect [29]. Other sleep disorders such as restless leg
syndrome or sleep apnoea may also occur in patients with
FMS.
FMS patients can experience important cognitive dys-
function, which associates with pain, but not current depres-
sion or anxiety, and includes poor working memory, spatial
memory alterations, free recall, and verbal ﬂuency [30–32].
Cognitive symptoms are present in FMS even after adjusting
data for age, medications, education, and depression [31].
Cognitive changes were however no diﬀerent when com-
pared to other pain patients, suggesting that pain per se
mayaﬀectcognition[33].Althoughmostpatientsexperience
associatedsymptomsinvaryingdegree,itisnotrequiredthat
these be present for a diagnosis of FMS.
Patients with FMS are heterogeneous and attempts have
been made to group patients into categories to help direct
treatments and predict outcome [25, 34, 35]. Subgrouping
of patients with FMS according to psychological distress,
depression in particular, has been most commonly reported,
but longitudinal studies using subgroups to direct treatment
and predict outcome are still required. In a recent analysis
of over 3000 patients in various clinic settings in Germany,
patients could be subgrouped into 5 categories depending
upon pain characteristics and associated comorbidity of de-
pression [25]. It is however still premature to attempt to cat-
egorize patients in the clinical setting, other than to pay par-
ticular attention to psychological status.
FMS may accompany other medical, neurological, or
rheumatologic illnesses as a comorbid condition [36]. Con-
ditions that have been associated with FMS include amongst
others various rheumatologic conditions such as systemic
lupus erythematosis and rheumatoid arthritis as well as neu-
rologic disorders such as multiple sclerosis and postpolio
syndrome [36, 37]. It is important to appreciate that FMS
can coexist with these conditions in order to direct treatment
appropriately. For example, a continuous complaint of pain
due to FMS in a patient with rheumatoid arthritis would
be incorrectly treated by increasing treatments with disease
modifying agents, rather than addressing the symptoms as-
sociated with FMS.
2.3. The Conundrum of Criteria for Diagnosis of Fibromyalgia.
Criteria for the classiﬁcation of FMS were established almost
two decades ago and take into account only the symptom of
pain [4]. Although the cardinal symptom of FMS remains
pain,symptomsoffatigue,sleepdisturbance,cognitivechan-
ges, mood disorder, and other somatic symptoms contribute
to the complexity of this syndrome [19].
The original 1990 criteria for classiﬁcation of FMS pose
at least 2 important practical problems [4]. Firstly, they were
developed speciﬁcally for the purpose of identifying patients
for further research in this condition, and secondly, they
addressed only the complaint of pain by means of a report of
pain and examination of tender points. These criteria were
often erroneously used to validate a diagnosis in individual
patients in the clinical setting and did not take into account
any other concomitant symptoms or severity of symptoms.
According to the 1990 criteria for a classiﬁcation of FMS,
in addition to widespread body pain, tender points were re-
quired to be present in at least 11/18 designated areas [4].
Tender points are located at soft tissue sites and reﬂect
a reduction in pain threshold without underlying tissue
pathology. Tender points have elicited considerable debate
and their true value has been questioned. Tender point
examination is a subjective test, open to individual interpre-
tation and reﬂects an overall reduction in pain threshold,
rather than a pathological process at the soft tissue site
[38]. They may be present in normal individuals and can
increase with age. Reliability is variable, ranging from good
to poor [39, 40]. The association of pain report and tender
point count is however poorly correlated, suggesting that
these measurements represent diﬀerent parameters of pain
experience in FMS [41].
The correct examination method for tender points is
also debatable. Methods that have been used include digital
palpation, myalgic scoring, or dolorimetry [42]. Although
digital examination is the most commonly used method of
assessment, it is often not used by physicians caring for FMS
patients [5]. There is also report of poor concurrent validity
when tender points were examined digitally or by dolorime-
try [43]. A person’s current psychological state has been
shown to inﬂuence measurement of tender points suggesting
an association with distress rather than an accurate indicator
of pain [44]. It has even been suggested that the examination
of a few selected points may be suﬃcient to identify FMS
[45]. It is also argued that tender points can be faked, and
that they truly bear no consequence to the composite of
suﬀering of FMS.
Takingintoaccountthepresenceofsymptomsotherthan
pain and the questions posed by tender points, new criteria
for a diagnosis of FMS have recently been published [5].
These new criteria, which may be viewed as complementary
to the 1990 criteria, with the elimination of the tender point
examination, perform well in identiﬁcation of patients with
a previous diagnosis of FMS [5]. The new criteria therefore
have included other symptom domains and made them an
essential part of the criteria set. However, elimination of
tender points also decreases speciﬁcity. Thus, unlike the 1990
ACR criteria, the new 2010 criteria require exclusion of other
conditions causing pain. Further, these criteria have not been
validated in primary care setting. A recent German working
group has concluded that FMS not only can be diagnosed
for clinical purposes on the basis of symptoms without a
tender point examination, but may also be established
using the old 1990 ACR criteria [46]. Therefore, wisdom
suggests that a clinical diagnosis of FMS today should not4 Pain Research and Treatment
bedependentsolelyuponasubjectivecountoftenderpoints,
but physicians may continue to use them for the present time
in order to help solidify a diagnosis, as well as diagnosis of
concomitant diseases, including depression [44, 47].
2.4. Fibromyalgia Is No Longer a Diagnosis of Exclusion. As
early as 1989, Yunus has advocated that a diagnosis of FMS
should not be made by exclusion, but rather by positive as-
sessment of a constellation of symptoms [48]. Additionally,
this clinical diagnosis should be made in the primary care
setting without need for excessive and costly investigation or
repeated specialist referral [16]. A detailed medical history
and good physical examination can be used to exclude other
rheumatologic conditions [8, 49].
Primary care physicians will be the ﬁrst to evaluate and
manage patients with a complaint of body pain due to FMS
[16, 50, 51]. Family physicians are likely best suited for the
careofthesepatientsinviewofthemultiplicityofcomplaints
and need for therapies that span many categories [16]. It is
also questionable whether there is truly a need for the di-
agnosis to be conﬁrmed by a medical specialist such as a
rheumatologist. The value of specialist opinion should be
for the patient in whom some other condition requires ex-
clusion, rather than to conﬁrm the diagnosis of FMS.
The clinical presentation of FMS can however be quite
diversewithsomeareasofthebodymorepainfulthanothers,
ﬂuctuations in intensity of pain and variable intensity of
other associated symptoms. Patients also diﬀer considerably
in terms of severity of functional impairment [52, 53]. This
awareness of diﬀerences in presentation and heterogeneity
of FMS is increasingly appreciated and is helpful to the
clinician.
It is also time to dispel the fallacy that FMS is a primary
psychogenic condition. As mentioned earlier, depression and
FMS are biologically diﬀerent conditions and depression is
present in any chronic diseases, including those with organic
pathology,suchascancerandcoronaryarterydiseases.There
isnoquestionthatthepsycheandthebodyaretightlylinked.
Illness, particularly prolonged and poorly recognized, fosters
mood disturbance. Conversely, mood disorder is associated
with reduced motivation to be physically active, resulting
in muscle deconditioning and subsequent pain complaint.
FMS patients have a greater prevalence of lifetime as well
as current mood disorder compared to other populations,
but this should not be viewed as causative in each and every
patient. It is possible that a vulnerable psychological status
may predispose an individual to onset of a pain process,
particularly if triggered by some event [54–56].
A clinical evaluation can be used to exclude most other
conditions that could masquerade as FMS [49, 57]. Some
common medical conditions that should not be missed in
a patient presenting with chronic widespread pain include
hypothyroidism, statin-induced myopathy, and polymyalgia
rheumatica, especially in the older patient. These are familiar
to primary care physicians and should not cause confusion.
Of greater concernis that a diﬀu s ep a i ns y n d r o m em a ye i t h e r
herald or mask a treatable rheumatologic condition such as
rheumatoidarthritis,systemiclupuserythematosis,oraneu-
rological illness such as multiple sclerosis, although this has
only rarely been recorded in a few prospective studies.
3. What Causes Fibromyalgia?
Although the exact cause of FMS is unknown, abnormalities
of nervous system pain processing can plausibly explain
the persistence of pain in the absence of tissue damage
[58]. The reason for this dysregulation is likely dependent
upon a number of interacting factors, which include genetic
predisposition, neurophysiological changes, and abnormal
stress response. As following articles in this publication will
elaborate further on pathogenesis, we will provide only a
brief overview.
3.1. Genetic Factors. The evidence for genetic predisposition
stems from studies showing familial aggregation of FMS
[59, 60]. The odds ratio for a diagnosis of FMS was reported
as 8.5 for a patient with a ﬁrst-degree relative with FMS
compared to having a relative with rheumatoid arthritis
[60]. Familial aggregation should be a clue for some genetic
contribution, but does not concretely prove a genetic link, as
factors such as environment or a triggering event need to be
takenintoconsideration.CandidategenesimplicatedinFMS
include those controlling serotonin mechanisms, dopamine
receptors, as well as metabolism of catecholamines [7, 61].
3.2. A Vulnerable Psychosocial Setting. Psychologic and
stress-related factors are the second area of consideration
regarding pathogenesis of FMS. Up to 40% of patients’
report the onset of symptoms preceded by some triggering
event, which might be either psychological or physical [62].
An abnormal physiological response to a stress mechanism
could explain this phenomenon [54–56]. Impairment of
the stress response, as measured by hypothalamo-pituitary-
adrenal(HPA)axisresponse,wasidentiﬁedpriortotheonset
of chronic widespread pain in a prospective population-
based study in England [63]. Psychological factors therefore
play an important role in neurophysiological responses and
have even been shown to aﬀect changes at the spinal level
[64].
Although FMS patients have a greater lifetime frequency
of depression [65], depression per se appears not to be a
direct causative factor in the pathogenesis of FMS [66]. Psy-
chological symptoms, of which depression and anxiety are
the most common, are however present in between 30 and
80% of FMS patients and contribute to poor global health
[66].
3.3. Neurophysiological Changes. The concept of a neuro-
logical versus a purely somatoform disorder to explain the
pathogenesis of FMS continues to stimulate debate [1, 67].
There is however convincing documentation of changes at
various levels of the nervous system supporting an ab-
normality that is primarily neurogenic and will be further
elaborated in ensuing articles in this supplement. A recent
development in the pathophysiology of FMS is that it isPain Research and Treatment 5
characterized by central sensitization (CS), well documented
in the laboratory setting [20, 21, 68]. CS also binds FMS
to other similar syndromes, for example, IBS and TMD,
collectively known as central sensitivity syndromes [20, 21].
Chronic pain, as occurs in FMS, may be perpetuated
by numerous interacting mechanisms, including increased
excitation or reduced inhibition [58, 69]. Neurophysiologic
studies have demonstrated evidence of dysfunctional central
pain mechanisms including spinal hyperexcitability [68, 70],
changes in thalamic and cortical pain matrix, as well a grey
matter volume [71, 72], and impaired function of normal
descending inhibitory mechanisms [73, 74]. In simple terms,
there is evidence for excessive pain-related neuronal activity
at multiple levels of the central nervous system, structural,
and functional changes in the brain by imaging studies and
impaired function of normal descending inhibitory mecha-
nisms.
4. Treatment Challenges
Treatments will be fully addressed in another article of this
supplement. We will however provide a brief introduction
by emphasizing new concepts that apply to management of
FMS. Firstly, the concept of symptom-based treatments is
logical and will allow a focussed starting point for a physi-
cian. Secondly, in the setting of no single “gold standard”
treatment, a multimodal approach which includes both non-
pharmacologic and pharmacologic treatments is rational
[75–77]. In this regard, patient education with emphasis
on an active role of the patients is critical. A patient-cen-
tred approach with individualization of management is very
important.
Finally, as patients with FMS commonly report sensi-
tivity to medications, clinical experience suggests that low
doses of medications can be used, with gradual increase
in dose depending upon eﬃcacy and tolerability. It is the
authors’experiencethatdosesofmedicationsusedinreallife
clinical practices are often much lower than those reported
in industry-controlled studies. It is also notable that many of
the adverse eﬀects of medications present symptoms similar
to those experienced by patients with FMS. Therefore, any
patient being treated with a medication should be carefully
evaluated for both eﬃcacy as well as side eﬀects, and medi-
cations should be discontinued unless there is evidence for
deﬁnite beneﬁt. In addition, combinations of medications
are also more commonly used in practice, although there is
limited evidence to support this practice from randomised
clinical trials.
AkeyprincipletomanagementofpatientswithFMSisto
encourage a shift of locus of control towards the patient and
to ensure that the patient is an active rather than a passive
participant in management. Understanding and support
should form the cornerstone of care for these patients, with
treatment strategies directed towards psychological status
andphysicalsymptomswithinthecontextoffamilyandsoci-
ety. Most patients will eventually with time ﬁnd some treat-
ment modality which will at least somewhat modulate, but
not cure symptoms, improve health status globally and im-
prove function.
Evidence-basedtreatmentguidelinesincludethosedevel-
oped by the American Pain Society (APS) in 2005 and the
European League Against Rheumatism (EULAR) in 2008
[49, 78]. Recent reviews of treatment options state that
there is good to moderate evidence for eﬃcacy of over 20
treatmentinterventionsinFMS,highlightingtheuncertainty
in management of these patients [79]. Approval of several
drugs by the FDA in recent years, for example, pregabalin,
duloxetine, and milnacipran, has been of great help in
alleviating symptoms. Other medications may also be used
[77].
Nonpharmacologic treatments are an important com-
ponent of management and recommended in both sets of
guidelines. These might include a tailored exercise pro-
gram, water therapy, physiotherapy, relaxation, cognitive be-
havioural training, and psychological support [80].
5. Outcome Is Not UniversallyBleak
Factors that can help predict the outcome for patients with
FMS are as yet not fully understood, but patients that do
well are more likely to be engaged in physical activity and
use less medication. Realistic outcome goals should be
emphasized. Reduction of symptoms should be translated
into improved functional status. When a patient reports
improvement in symptoms without a parallel functional
change, the physician should question ﬁrst the true eﬃcacy
of the treatment, secondly the side eﬀect proﬁle which might
becontributingtopooreﬀectonfunction,andﬁnallypatient
motivation to achieve an improved health status.
A study of outcome done by postal questionnaire in
the USA suggested continued pain and disability, with little
change over time [52, 53]. However, publications from
Australia, Mexico, and Canada have reported a more fa-
vourable outcome [81–83]. In a Canadian prospective study
ofFMSpatients,almost50%reportedaclinicallymeaningful
improvement in overall status of FMS over a 3-year observa-
tion period [83]. This improvement in outcome is further
supported by the ﬁndings that 65% of subjects improved
over a 2-year period in a community-based study in England
[84].Goodlong-termprospectivestudiesarestilllackingand
many questions regarding prognosis and outcome remain
unresolved.
6. Conclusion
There is accumulating and ample evidence in the scientiﬁc
literature to support the existence of FM as an entity and
as a diagnosable condition by its own characteristic features,
even in the absence of an objective clinical test. There has
been a substantial progress in an understanding of the
pathophysiology of FMS in the past 20 years. Now it is
known that it is a neurobiological disease. The mechanisms
predominantly involve central sensitization, contributed by
genetics, endocrine factors, poor sleep, psychosocial and
physical stress, and physical trauma.6 Pain Research and Treatment
The initial clinical challenge is to correctly diagnose
FMS on the basis of patient report and in the absence of
an objective clinical test to conﬁrm diagnosis or gauge
severity of symptoms. Therefore, the accurate recognition of
FMS and assessment of response to treatments still require
the time-honoured art of clinical medicine [85]. There is
currently no cure for FMS, and no single treatment is
universally eﬀective for control of pain and the associated
features of this condition. Even in the absence of complete
understanding of cause and pathogenesis, treatments can
be directed to alleviate symptoms with the goal to improve
functional status. Global outcome with attention to overall
well-being represents a more realistic outcome measure that
is both clinically applicable and pertinent to the patient.
The translation of the knowledge of the pathogenesis of
FM has however greatly facilitated introduction of treatment
options, including use of pharmacological agents, that are
ﬁnally beginning to show promise for the management of
this illness.
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